{"id":4088,"date":"2022-02-25T09:49:55","date_gmt":"2022-02-25T09:49:55","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&#038;p=4088"},"modified":"2022-02-25T09:49:55","modified_gmt":"2022-02-25T09:49:55","slug":"dr-noa-krugliak-cleveland-m-d-ccc-2022-vedolizumab-in-ulcerative-colitis-data-from-ralee","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/digestive-disorders\/conference-hub\/dr-noa-krugliak-cleveland-m-d-ccc-2022-vedolizumab-in-ulcerative-colitis-data-from-ralee\/","title":{"rendered":"Dr Noa Krugliak Cleveland M.D., CCC 2022: Vedolizumab in Ulcerative Colitis &#8211; Data from RALEE"},"content":{"rendered":"<p><span style=\"font-weight: 400\">We were delighted to speak with Dr Noa Krugliak Cleveland M.D. (University of Chicago, Chicago, IL, USA) around her talk on the RALEE study, investigating the impact of early initiation of vedolizumab in UC.<\/span><\/p>\n<p><span style=\"font-weight: 400\">The abstract \u2018EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)\u2019 which was presented at the virtual 2022 Crohn\u2019s &amp; Colitis Congress, 20-22 January, 2022.<\/span><\/p>\n<p><b>Questions<\/b><\/p>\n<ol>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">What is known about the effect of timing of initiation of biologic therapies in ulcerative colitis? (0:10)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">What were the aims and design of the RALEE<\/span> <span style=\"font-weight: 400\">study? (0:58)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">What did the study tell us about patient characteristics and treatment patterns? (1:28)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">What can be done to ensure treatment patterns more closely match the guidelines? (2:13)<\/span><\/li>\n<\/ol>\n<p><b>Disclosures:<\/b><span style=\"font-weight: 400\"> Noa Krugliak Cleveland discloses consulting for Takeda.<\/span><\/p>\n<p><b>Support:<\/b><span style=\"font-weight: 400\"> Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.<\/span><\/p>\n<p><b><i>Filmed in coverage of the virtual Crohn\u2019s &amp; Colitis Congress 2022.<\/i><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We were delighted to speak with Dr Noa Krugliak Cleveland M.D. (University of Chicago, Chicago, IL, USA) around her talk on the RALEE study, investigating the impact of early initiation of vedolizumab in UC. The abstract \u2018EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)\u2019 which was presented [&hellip;]<\/p>\n","protected":false},"featured_media":4089,"template":"","class_list":["post-4088","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-digestive-disorders","video_categories-ccc-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/4088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":3,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/4088\/revisions"}],"predecessor-version":[{"id":4092,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/4088\/revisions\/4092"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/4089"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=4088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}